Kingston, Jamaica – a student researcher, Dr. Charisse Best, calls for help and breast cancer patients to their physician to be aware of the increased risk of cardiovascular disease and made some recommendations.
Best, who was the winner of the best student entries at the ninth annual national health research conference in 2018, shared the findings of its research awards at the recent JIS «Think Tank».
progamme study was done in partial fulfillment of her Doctor of Medicine (DM) degree, and was named the prevalence of risk factors for cardiovascular disease in patients with breast cancer treated with anthracycline-based University Hospital of the West Indies.
"The study looked at the basic risk factors for cardiovascular disease associated with that patient risk factors, some of which we can not do anything about (age, ethnicity, and gender), and modifiable risk factors such as hypertension, diabetes and obesity, "she said.
"We also looked at treatment-related risk factors, which, although useful, some procedures can affect the heart," she added.
According to Dr. Best, who & # 39 is resident in the University Hospital of the West Indies and of the Postgraduate Program of Hematology and Oncology, the study also looked at the measures that have been implemented to modify risk factors.
The study showed that 78 percent of patients with non-metastatic breast cancer who were treated with anthracycline-based therapy, which is a & # 39 is one of the standard treatments for breast cancer, in fact, at least one factor the risk of developing cardiovascular disease, which she said is quite alarming percentage.
Non-metastatic cancer is not transmitted from the primary or original site to other parts of the body.
With 78 percent, the highest rate of obesity was 42 percent, followed by high blood pressure by 36 percent.
"We also noted that 10 percent of patients had a history of smoking and 10 percent had a history of diabetes," she said.
Best noted that breast cancer is a & # 39 is the most common form of cancer diagnosed in women in Jamaica and around the world, and that the survivors is growing over the years.
She added that, on the contrary, cardiovascular disease with & # 39 are the most common cause of death both in the world and in Jamaica.
It was also noted that all patients in the study had a history of being treated with anthracyclines, 53 percent of which were also treated with radiation cell wall thoracic and five percent of Trastuzemab, an antibody that is used in the treatment of cancer.
"These treatments, although useful, can increase the risk of developing cardiovascular disease, so we want to look at the profile of risk factors before starting the procedure to see if we can change the risk factors for these treatments," said Dr. Best.
She said that although the study was not designed to determine how many patients developed cardiovascular disease after treatment, the team had some interesting results.
"What we have noticed that those who had more than three risk factors for heart failure, as a rule, heart failure, so we looked at some of the implementations that have been made to study," she explained.
"For patients with hypertension, who came to the clinic of oncology, only 29 percent of them were on hypertension treatment and we have also noted that, although most of them have an echocardiogram before treatment, only four percent received after echocardiography. Although we were not able to say why this is so, then we have in mind that for most of them it was a financial issue, "she said.
Rather, it is recommended from the results of this study with the & # 39 is that patients and general practitioners should be aware that these patients are at high cardiovascular risk, so much remains to be done to change their cardiovascular risk factors such as hypertension and diabetes, and they also need to increase physical activity and reducing obesity.
According to Dr. Best, it would also be good to put patients at the heart-protective agents such as ACE inhibitors and hypertension encourage echocardiogram at least six to 12 months after their therapy.
Angiotensin converting enzyme inhibitors, or ACE inhibitors & # 39 are drugs that slow down or inhibit the activity of the enzyme.
The study was conducted a retrospective study of 284 patients with non-metastatic breast cancer patients diagnosed in 2006 to 2015 was conducted under the direction of Dr. Best Dr. Sheray Chin and Dr. Gillian Wharf in the department of pathology at the University of the West Indies.
Now you can read at any time Jamaica Observer ePaper, anywhere. Jamaica Observer ePaper is available to you at home or at work, and the same edition of the printed copies are available on http://bit.ly/epaperlive